Project B10 (new)

To be able to define the amount of the proteasome inhibitors bortezomib and carfilzomib that needs to be released in vivo, sensitivity of myeloma cells, osteoblasts, osteoclasts and their progenitors regarding viability/proliferation will be assessed, and the effect on differentiation will be characterized. Furthermore, intracellular distribution processes are investigated and correlated with effect data (proteasome inhibition). These data will be combined with the distribution of the compounds in vivo and their locally reachable concentration. Expression of drug transporters will be assessed using RNA-sequencing and correlated with differences in cellular sensitivity.

Principle Investigators (PI)
Dr. rer. nat. Jürgen Burhenne Bereichsleiter Analytisch-Chemisches Labor    Abteilung Klinische Pharmakologie und Pharmakoepidemiologie Universitätsklinikum Heidelberg Contact: Im Neuenheimer Feld 410 69120 Heidelberg Telefon: 06221/56-36395 Email: juergen.burhenne@med.uni-heidelberg.de
Prof. Dr. rer. nat. Johanna Weiß         Bereichsleiterin Molekularbiologisch-Biochemisches Labor             Abteilung Klinische Pharmakologie und Pharmakoepidemiologie Universitätsklinikum Heidelberg Contact:      Im Neuenheimer Feld 410 69120 Heidelberg Telefon: 06221/56-39402 Email johanna.weiss@med.uni-heidelberg.de
Dr. med. Anja Seckinger Wissenschaftliche Mitarbeiterin Labor für Myelomforschung Medizinische Klinik V Universitätsklinikum Heidelberg und Nationales Centrum für Tumorerkrankungen Heidelberg Contact: Im Neuenheimer Feld 410 69120 Heidelberg Email: anja.seckinger@med.uni-heidelberg.de